George Whitney joins Kyowa Hakko USA as Director of Business Development

George Whitney joins Kyowa Hakko USA as Director of Business Development

New York, March 23, 2010 - George Whitney has joined the Kyowa Hakko USA sales and marketing department as director of business development for pharmaceutical bulk products. The announcement was made by Leo Cullen, Kyowa Hakko USA vice president of sales and marketing.

Whitney's primary responsibilities will include the development of Kyowa Hakko Bio technology and products within the pharmaceutical industry focusing on cell culture, medical foods, active pharmaceutical ingredients (APIs), intermediates and diagnostic reagents. Additionally, Whitney will seek out opportunities to integrate production capabilities of Daiichi Fine Chemicals, Inc., targeting development of APIs and intermediates. Whitney will be based in the New York office.

Whitney has more than 25 years of experience in the biotechnology field and has held various positions in process development, R&D, bio-fermentation production, sales and marketing and business development. Most recently Whitney was associate director of sales and business development for the custom manufacturing group at Lonza Group Ltd. He holds a Bachelor of Science degree in Biology from Stockton State College and Masters of Science Degree from Trenton State College.

"George Whitney's technical training and experience in the biotech field will allow Kyowa Hakko USA to expand its business activities in the pharmaceutical market beyond our traditional applications, said Cullen.

Kyowa Hakko is an international health ingredients manufacturer and world leader in the development, manufacturing and marketing of pharmaceuticals, nutraceuticals and food products. Kyowa is the maker of branded ingredients including Cognizin® Citicoline, HydrafendTM Hyaluronic Acid, Lumistor® L-Hydroxyproline, Setria® Glutathione, Kyowa CoQ10TM as well as SustamineTM L-Alanyl-L-Glutamine. Kyowa offers manufacturers and formulators one of the industry's most extensive lines of over 50 amino acids and related compounds, including D-Amino acids and branch-chain amino acids, as well as nucleic acids, bio-products and fine chemicals.

Additional can be found online at or contact Kyowa Hakko USA at [email protected] or 212.319.5353.


Sheldon Baker

Baker Dillon Group

P.O. Box 689

Clovis, CA 93613


559.325.7195 Fax

[email protected]


Suggested Articles

CureVac named a permanent CEO, Franz-Werner Haas, and signed Novartis alum, Igor Splawski, Ph.D. as its new top scientist.

J&J studied the drug in midphase obesity clinical trials, but Merck sees it as a potential treatment for nonalcoholic steatohepatitis.

The Big Pharma paid $134 million to enter into the two partnerships but then dropped the projects after Voyager completed research activities.